Leucine derivatives

A pharmaceutical composition for administration to a patient comprising

• (a) about 5% to about 95% of a compound of formula ##STR14## wherein A is the group ##STR15## or --(CH.sub.2).sub.5 -- said composition being present in a amount sufficient to supply about 0.1 to about 100 mg of compound I per kilogram of body weight of the patient per day;
• and
• (b) 5% to 95% of a pharmaceutically acceptable inert carrier material, said composition being formulated in a unit dosage form.

A method of treating obesity in an afflicted mammal comprising administering to the mammal a compound of the formula ##STR16## wherein A is the group ##STR17## or --(CH.sub.2).sub.5 -- in an amount which is effective in treating obesity.

A method of treating hyperlipaemia in an afflicted mammal comprising adminstering to the mammal a compound of the formula ##STR18## wherein A is the group ##STR19## or --(CH.sub.2).sub.5 --, in an amount which is effective in treating hyperlipaemia.

A method of preventing obesity in a mammal comprising administering to the mammal a compound of the formula ##STR20## wherein A is the group ##STR21## or --(CH.sub.2).sub.5 --, in an amount which is effective in preventing obesity by inhibiting pancrease lipase.